Moderna reaffirms annual COVID vaccine sales forecast
Tweet
Share
E-mail
FILE PHOTO: Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) - Moderna on Monday reaffirmed its forecast of $6 billion to $8 billion in COVID vaccine sales for the year, after rival Pfizer slashed forecast for its vaccine last week.
Moderna said it will have "improved visibility" about the expected U.S. market size for vaccines after observing trends through October 2023.
Shares of Moderna were down about 4% in premarket trading.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Reiterates Neutral Rating on Moderna (MRNA)
- Anthropic’s Claude finds new enzyme system
- Moderna shares climb on cancer vaccine momentum
Create E-mail Alert Related Categories
General News, Guidance, ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
